A decision to give Palantir Technologies a major role in the National Health Service’s Federated Data Platform is fueling one of the biggest debates in UK healthcare. What was sold as a practical fix for creaking data systems and stubbornly long waiting lists has instead opened up a much messier conversation about privacy, ethics, and who really benefits when a controversial American tech company gets its hands on some of the most sensitive public data in the country.
Palantir isn’t a company that generates neutral reactions. Its data analytics tools are genuinely powerful, but its track record — built substantially on contracts with military, intelligence, and immigration agencies — follows it everywhere it goes. In the UK, Medact has come out strongly against the arrangement, urging NHS trusts and Integrated Care Boards to walk away from the platform entirely and calling on NHS England to cancel the contract outright, citing serious concerns around ethics and governance.
The way Palantir has approached the UK public sector more broadly has also raised eyebrows — critics describe a deliberate strategy of embedding itself so deeply in essential infrastructure that unpicking it later becomes impractical. The way they got the contract is also under fire, with claims of aggressive lobbying. And, of course, privacy is a huge worry — the platform pools massive amounts of patient data, making people question what safeguards are in place for the long run.
The whole point of the Federated Data Platform is to link up data from different hospitals to help manage patient flow, cut waiting lists, and improve decision-making. But the critics aren’t arguing against better data use in the abstract — they’re arguing about who controls it and what happens to it down the line. Some experts are even warning that, while there are rules now to stop data from being shared too widely, a future government could easily change them. The headlines haven’t helped, with some calling the deal an “open door to government abuse,” and doctors and activists even calling for a boycott against an “ethically bankrupt” company.
But not everyone is against it. Some people, especially those focused on making the NHS run better, are all for it. They argue Palantir’s tech could streamline everything, shrink those endless waiting lists, and make the most of tight resources. There are already a few early examples where hospitals have used similar tools to manage patients more effectively, which supporters are pointing to as proof that it can work.
Where the public lands on all this is harder to pin down — opinions split pretty cleanly between those who see the partnership as an overdue and necessary modernization and those who view it as a troubling line being crossed. NHS England’s official position is that patient data stays under its control throughout, and Palantir has consistently said it neither owns nor profits from NHS data and is committed to operating transparently.
